Barclays’s Cogent Biosciences COGT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.3M | Buy |
320,565
+145,647
| +83% | +$1.05M | ﹤0.01% | 2136 |
|
|
2025
Q1 | $1.05M | Sell |
174,918
-18,150
| -9% | -$109K | ﹤0.01% | 2420 |
|
|
2024
Q4 | $1.51M | Buy |
193,068
+17,384
| +10% | +$136K | ﹤0.01% | 2387 |
|
|
2024
Q3 | $1.9M | Buy |
175,684
+97,541
| +125% | +$1.05M | ﹤0.01% | 2216 |
|
|
2024
Q2 | $660K | Sell |
78,143
-29,510
| -27% | -$249K | ﹤0.01% | 2361 |
|
|
2024
Q1 | $724K | Sell |
107,653
-121,552
| -53% | -$817K | ﹤0.01% | 2613 |
|
|
2023
Q4 | $1.35M | Buy |
229,205
+118,293
| +107% | +$696K | ﹤0.01% | 2413 |
|
|
2023
Q3 | $1.08M | Sell |
110,912
-1,481
| -1% | -$14.4K | ﹤0.01% | 2040 |
|
|
2023
Q2 | $1.33M | Buy |
112,393
+4,595
| +4% | +$54.4K | ﹤0.01% | 1979 |
|
|
2023
Q1 | $1.16M | Sell |
107,798
-71,694
| -40% | -$773K | ﹤0.01% | 2029 |
|
|
2022
Q4 | $2.08M | Buy |
179,492
+31,236
| +21% | +$361K | ﹤0.01% | 1622 |
|
|
2022
Q3 | $2.21M | Buy |
148,256
+145,473
| +5,227% | +$2.17M | ﹤0.01% | 1592 |
|
|
2022
Q2 | $25K | Sell |
2,783
-31,359
| -92% | -$282K | ﹤0.01% | 3999 |
|
|
2022
Q1 | $257K | Buy |
+34,142
| New | +$257K | ﹤0.01% | 3164 |
|
|
2020
Q3 | – | Sell |
-1,869
| Closed | -$3K | – | 3748 |
|
|
2020
Q2 | $3K | Buy |
+1,869
| New | +$3K | ﹤0.01% | 3708 |
|
|
2020
Q1 | – | Sell |
-6,338
| Closed | -$18K | – | 3680 |
|
|
2019
Q4 | $18K | Sell |
6,338
-261
| -4% | -$741 | ﹤0.01% | 3695 |
|
|
2019
Q3 | $38K | Sell |
6,599
-7,958
| -55% | -$45.8K | ﹤0.01% | 3739 |
|
|
2019
Q2 | $152K | Buy |
14,557
+13,120
| +913% | +$137K | ﹤0.01% | 3355 |
|
|
2019
Q1 | $25K | Buy |
+1,437
| New | +$25K | ﹤0.01% | 3860 |
|
|
2018
Q4 | – | Sell |
-1,587
| Closed | -$65K | – | 4128 |
|
|
2018
Q3 | $65K | Buy |
1,587
+1,522
| +2,342% | +$62.3K | ﹤0.01% | 3626 |
|
|
2018
Q2 | $4K | Buy |
+65
| New | +$4K | ﹤0.01% | 4021 |
|